ArticleEuropean journal of preventive cardiology2025
Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population.
Article in European journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Heterogeneity in Lipoprotein(a) Profile Changes Across the Menopausal Transition.European journal of preventive cardiology · 2026Article
- Observational study: Temporal dynamics of lipoprotein(a) after out-of-hospital cardiac arrest: The Biobank Working Group.Resuscitation plus · 2026Article
- Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Use of Coronary Artery Calcium Scoring in Individuals With Elevated Lipoprotein(a): A Multicohort Study.Journal of the American College of Cardiology · 2026Article
- Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study.Journal of clinical medicine · 2026Article
- Intraindividual Lp(a)-Variability in a Real-World Setting.JACC. Advances · 2026Article
- Article
- Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome.Journal of clinical medicine · 2026Review
- A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions.Korean circulation journal · 2026Review
- A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions.Journal of lipid and atherosclerosis · 2026Review
- Is a Single Lipoprotein(a) Measurement Once in a Lifetime Sufficient? The Results from the STAR-Lp(a) Study.Medical sciences (Basel, Switzerland) · 2025Article
- Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights.American journal of preventive cardiology · 2025Review
- Outcomes after coronary angiography in individuals with elevated lipoprotein(a).European journal of preventive cardiology · 2025Article
- Characterizing Lipoprotein(a) in Children With New-Onset Diabetes and Implications for Cardiovascular Risk Assessment.Journal of the Endocrine Society · 2025Article
- Lipoprotein(a) at a "Tipping Point": case to move to universal screening.American journal of preventive cardiology · 2025Review
- Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk.Lipids in health and disease · 2025Observational
- Lipoprotein(a) and cardiovascular risk: new insights.European journal of preventive cardiology · 2025Article
- Lipoprotein(a): Assessing the Current Knowledge and Gaps in Screening and Treatment-A Narrative Review.Journal of cardiovascular development and disease · 2025Review
- Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.Biomolecules · 2025Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLipoprotein(a) (Lp(a)) levels are known to be mainly genetically determined. However, only scarce data are available on the intra-individual variability of Lp(a) levels across time. METHODS AND
resultsWe included adult patients (≥18 years old) who had baseline and follow-up Lp(a) measurements (between 1997 and 2024) with a minimum of 1 year apart. Patients were categorized into three groups as follows: normal (<30 mg/dL), borderline (30 to 50 mg/dL), and high Lp(a) (≥50 mg/dL). Multivariable logistic regression was conducted to assess the predictors of the intra-individual changes in Lp(a) ≥ 10 mg/dL. A total of 11 669 individuals (median age: 54 years, 60% males) were included in our analysis, with median time between measurements of 4.5 years [interquartile range (IQR): 2.2, 10.6]. The median Lp(a) was 16 mg/dL (IQR: 7, 52) at baseline, compared with 15 mg/dL (IQR: 7, 52) at follow-up. At follow-up, 96.4% of individuals with normal Lp(a) and 89.9% with high Lp(a) remained in their categories, while 51.2% with borderline Lp(a) changed their category. Of the included population, 24.9% had an intra-individual Lp(a) change ≥ 10 mg/dL. Female sex (P < 0.001), history of ASCVD (P = 0.003), statin therapy (P = 0.003), and elevated LDL cholesterol (LDL-C) levels ≥ 100 mg/dL (P < 0.001) were significantly associated with higher odds of intra-individual Lp(a) changes ≥ 10 mg/dL.
conclusionLipoprotein(a) levels were generally stable over time; however, patients with borderline levels may require more than one Lp(a) measurement, especially if they are females, have a history of ASCVD, have elevated LDL-C levels, or are on statin therapy.
Indexed as
Identifiers
39447040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.